Compare Crispr Therapeutics AG (CRSP) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Redwire Corporation — how do they compare? Crispr Therapeutics AG trades at $53.82 (market cap $5.23B), while Redwire Corporation trades at $13.57 (market cap $3.38B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Redwire Corporation is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | RDW | |
|---|---|---|
Market Cap | $5.23B | $3.38B |
Sector | Health | Technology |
52-Week High | $76.78 | $25.90 |
52-Week Low | $44.34 | $5.06 |
Enterprise Value | $3.65B | $2.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Redwire (RDW) trades at $13.57, up 3.43% with strong technical momentum as the stock approaches its consensus price target of $17.50. The company reported record Q2 2026 revenue of $117.1 million and a $542.1 million backlog, though it continues to post significant net losses with a -57.26% margin. Analyst sentiment remains overwhelmingly positive with 80% buy ratings, while technical indicators show bullish moving averages but overbought RSI conditions.
Redwire presents a growth story fueled by defense contracts and space technology, but faces substantial execution risk given persistent losses and negative cash flow from operations. The stock's upside depends on successful margin improvement and backlog conversion, while downside risk remains from dilution and delayed profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
